Research and Markets: Prostate Cancer: Vaccines and Therapeutic Antibodies - 2010

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/2465ba/prostate_cancer_v) has announced the addition of the "Prostate Cancer: Vaccines and Therapeutic Antibodies - 2010" report to their offering.

The prostate cancer immunotherapy pipeline is showing rapid development. Currently, there are 30 candidates in the pipeline (16 vaccines and 14 therapeutic antibodies), and one prostate cancer vaccine (Provenge) has recently been approved by the FDA.

First-line treatments for prostate cancer are largely based on anti-androgen drugs, or pituitary down-regulators. Other treatments include surgery, radiotherapy and chemotherapy. Resistance is commonly seen in the case of androgen-targeting drugs. Other therapies such as surgery and radiotherapy may be effective, but present increased risk. These treatment limitations have prompted efforts to develop safer, targeted therapies.

In April 2010, Dendreon Inc. received FDA approval for its vaccine, Provenge an autologous cellular immunotherapy developed for metastatic prostate cancer. This vaccine is based on the use of patients own peripheral blood mononuclear cells, following prior treatment with a Prostate Acid Phosphatase/Granulocyte-Macrophage Colony-Stimulating Factor (PAP/GM-CSF) fusion protein. PAP is a commonly expressed prostate cancer antigen.

The development of new candidate vaccines and therapeutic antibodies to target prostate cancer, is showing rapid progress. There are 30 candidates in the pipeline (16 prostate cancer vaccines and 14 prostate cancer-targeting antibodies), and one FDA-approved prostate cancer vaccine (Provenge). Of these candidates, 19 are at Phases II and III (nine vaccines and 10 antibodies) and eight are at Phase I.

These vaccines and antibodies are targeting more than fifteen different prostate cancer-associated antigens or other prostate cancer-associated proteins, and are being taken forward by 25 companies: 20 small and medium sized enterprises, and five multinational pharmaceutical companies.

This report provides a comprehensive update on the prostate cancer immunotherapy pipeline, and includes summary pre-clinical and clinical findings (pre-clinical to Phase III) on the candidate vaccines and antibodies presented.

This report provides:

  • A comprehensive update on the prostate cancer vaccine and therapeutic antibody pipeline;
  • Summary pre-clinical and clinical findings (where published) for all candidate vaccines and antibodies presented;
  • Descriptions of vaccine-targeting mechanisms (antigens and targets);
  • Details of development companies.

Key Topics Covered:

Chapter 1 Background

Chapter 2 Prostate Cancer Immunotherapy Strategies

Chapter 3 Approved Vaccine p.18

Chapter 4 Phase III Vaccines and Antibodies

Chapter 5 Phase II Vaccines and Antibodies

Chapter 6 Phase I Vaccines and Antibodies

Chapter 7 Preclinical & Research Vaccines and Antibodies

Chapter 8 Discussion

For more information visit http://www.researchandmarkets.com/research/2465ba/prostate_cancer_v



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.